Journal of the Pancreas Open Access

  • ISSN: 1590-8577
  • Journal h-index: 80
  • Journal CiteScore: 29.12
  • Journal Impact Factor: 19.45*
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +44 7460731551

- (2016) Volume 17, Issue 2

Extended Lymphadenectomy and "Mesopancreas" Excision during Pancreatoduodenectomy for Cancer; is it worth it? Review of Current Evidence

Elissaios Kontis1*, Evangellos Prassas2, Parthi Srinivasan2, Andreas A Prachalias2

12nd Department of Surgery, Aretaieion Hospital, University of Athens, Athens, Greece

2Institute of Liver Studies, King’s Health Partners at King’s College Hospital, London, United Kingdom

*Corresponding Author:

Elissaios Kontis
2nd Department of Surgery, Aretaieion Hospital
76 Vas. Sofias Avenue, 11528
University of Athens, Athens, Greece
Phone + 306972019700

Received September 08th, 2015 Accepted October 25th, 2015

Visit for more related articles at Journal of the Pancreas


Pancreatic cancer is a malignancy with overall poor prognosis. Surgery is the only treatment modality, which could provide cure. Therefore every effort possible should be made for pancreatectomy to achieve R0 resection. However, even after R0 resection, the survival outcomes are still far behind from other solid intrabdominal tumors. Extended lymphadenectomy and “mesopancreas” excision are the two main factors where focus has been given, in order to improve the outcomes of pancreatectomy for pancreatic head cancer. We present an up to date comprehensive review of the current evidence on the topics of extended lymphadenectomy and “mesopancreas” excision during pancreatoduodenectomy for cancer.


Lymph Node Excision; Pancreaticoduodenectomy; Pancreatic Neoplasms, Whipple Disease


Pancreatic head cancer is a malignancy associated with an overall grim prognosis; little improvement has been made at the survival between 1996-2007 with the 1-year survival remaining below 20% [1] and the predicted 10-year survival for patients diagnosed with pancreatic cancer between 2010 and 2011, to be merely 1.1% [2]. The major factor increasing patient survival is the ability for complete excision of the tumour site [3, 4]. Malignant tumors of the head of pancreas are resected by means of pancreatoduodenectomy also known as a Whipple’s procedure [5]. However even after a Whipple’s procedure the reported survival remains poor, with a median survival period of 11 to 20 months [6]. As with all malignancies of solid intrabdominal organs, two main reasons should be considered for a suboptimal survival outcome after an oncological procedure; inadequate lymph node clearance and inadequate tumor resection (R1). We present an up to date review of the abovementioned issues and their application in modern pancreatic surgery.

Surgical Anatomy of the Peripancreatic Lymph Nodes and “Mesopancreas”

Sir Andrew Watt Key has put in words the most comprehensive statement for the surgical anatomy of the pancreas: “For me, the tiger country is removal of the pancreas. The anatomy is very complex and one encounters anomalies” [7]. The pancreas stands at a bridging point between the celiac trunk axis and the superior mesenteric artery axis, within the retroperitoneum. The lymphatic drainage of the head of the pancreas is channeled towards four directions: i) to the superior pancreatic nodes towards, the left gastric nodes, ii) to the inferior pancreatic nodes, towards the superior mesenteric nodes and the paraortic lymph nodes, iii) the anterior pancreatic nodes including the anterior pancreatoduodenal and infrapyloric nodes and iv) the posterior pancreatic nodes including the posterior pancreatoduodenal towards either the retroportal lymph nodes, the paraortic lymph nodes or the superior mesenteric nodes [8]. This extended network of lymph nodes appears to correspond to the complex embryogenesis of the head of the pancreas from two pancreatic primordial, the dorsal and the ventral. Kitagawa et al. have supported that the lymphatic spread of the pancreatic head carcinoma follows two distinct patterns based on the location of the tumor and the embryologic division of the pancreas [9]. However as stated by Kitagawa et al. in his study, in the majority of their cases the tumor extended in both embryologic divisions (ventral and dorsal) of the pancreas [9], hence the clinical applicability of this concept may be limited.

Although gross anatomy anteriorly to the pancreas is crystal clear, what lies posteriorly to the pancreas is foggy. The pancreas is located within the retroperitoneum. Recently the concept of “mesopancreas” has emerged in order to define the retroperitoneal soft tissue lying posteriorly to the pancreas [3, 6, 10]. The mesopancreas refers to the soft tissue lying posteriorly to the pancreas comprising of loose areolar and adipose tissue, lymphatics, capillaries and nerve fibers [11]. However both the anatomical borders and its very existence has been debated and challenged.

All authors agree that the mesopancreas extends within the space defined anteroposteriorly by the posterior surface of the head of the pancreas and the anterior surface of the aorta [3, 6, 10]. Also unanimously, the medial border is considered the right aspect of the celiac trunk and superior mesenteric plexuses. However the lateral border according to Gaedcke and Gockel [3, 6] is considered the axis of the superior mesenteric vessels, while Adham [10] considers the level of the aortocaval recess, i.e. more laterally to the axis of the superior mesenteric vessels. In contrast, Agrawal et al. considers the concept of mesopancreas anatomically unfounded [11], based on the argument that this tissue is not clearly defined by a fascia layer. When considering the embryologic definition, a meson is the residual of a distinct developmental pathway [12], which does not clearly apply in the case of the pancreas. Moreover when considering other anatomical entities defined as a “meson” i.e. mesentery, the meson refers to an entity covered by two distinct serosal folds and contains the feeding vessels for the organ target as the mesentery is defined by two layers of splachnic peritoneal reflections and contain the mesenteric vessels for the bowel which is the target organ. To this end, Agrawal et al. are fully justified to consider a mesopancreas nonexistent; although the terminology may not be appropriate, the oncological value of this soft tissue is yet to be determined.

Lymphadenectomy during Pancreatoduodenectomy

Since the introduction of pancreatoduodenectomy in 1935 by A. Whipple and after it’s modification to an one stage procedure by Waugh and Clagett in 1946 [5], no other major modification to the standard technique has been made, with the exception of the introduction of Pylorus Preserving PancreatoDuodenectomy (PPPD) by Traverso and Longmire in 1978 [5]. A critical issue in regards to the surgical technique of pancreatoduodenectomy is the extent of the complemental regional lymphadenectomy, which has not been defined in the past and yet has to gain unanimity among surgeons. which has failed. In 1973, Fortner first introduced the concept of a more “wide” excision of the head of the pancreas, targeting the peripancreatic lymphatic drainage and the corresponding lymph nodes [13]. The need for the concept of a wider excision in pancreatic surgery emerged from the high local recurrence rates, reported to be as high as 30 to 70% [14]. The rationale was that residual disease within the peripancreatic lymph nodes would be the triggering site of locoregional recurrence. An initial report by Ishikawa in 1988 regarding extended lyphadenectomy showed an improved 3-year survival rate [15], thus initiating a consequent series of studies mainly originating from Japan for pancreatoduodenectomy accompanied with extended lymphadenectomy. However until 1998 and the report by Pedrazzoli et al. [16], there was a lack of randomized studies comparing the standard versus extended lymphadenectomy during pancreatoduodenectomy. Following the initial study by Pedrazzoli et al. three more studies [17-19] have been published addressing the issue of lymphadenectomy and today there are also available meta-analyses to evaluate the efficacy of extended lymphadenectomy [20-22]. As concluded unanimously in all available meta-analyses [20-22], extended lymphadenectomy has failed to provide a survival benefit to patients after pancreatodudodenectomy (Table 1). However, from a point of skepticism all these meta-analyses should be read with caution, since they have included the same four studies [16-19], hence as expected reported similar results. Despite the discouraging results of these meta-analyses, further study is needed before the issue of the pattern of lymph node metastasis in pancreatic cancer has been adequately addressed. The ratio of infiltrated lymph nodes in pancreatic head cancer along with the site of infiltrated lymph nodes still remain as significant prognostic factors of survival outcome [23-25]. Recently, the International Study Group on Pancreatic Surgery has published their recommendations on the extent of lymphadenectomy during pancreatoduodenectomy [26]. The adequacy of the proposed extent of lymphadenectomy is to be determined, by means of either observational studies or randomized control trials examining the effects of the proposed extent of lypmhadenectomy. Most importantly in this report by International Study Group on Pancreatic Surgery, no consensus was achieved on continuing or terminating the pancreatic resection in cases where positive lymphnodes are found outside the proposed field of lymphnode dissection [26]. Thus a focus on defining and avoiding R1 resection during pancreatectomy has gained significant importance. This process has resulted to the concept of mesopancreas.

Resection of “mesopancreas”

The concept of mesopancreas emerged in an attempt to explain the increased rates of locoregional recurrence and thus the poor survival outcomes after pancreatoduodenectomy for cancer of the head of the pancreas. The poor survival outcomes have been attributed to early lymph node involvement in pancreatic head carcer and the direct infiltration of cancer cells to the retropancreatic tissue [6]. Regarding the direct infiltration of cancer cells into the retropancreatic tissue, a parallel was extracted by the advancement in survival outcomes achieved in rectal cancer by the introduction of the concept of mesorectum by Heald [27]. The total mesorectal excision has been the surgical way forward for reducing the rate of pelvic recurrence in rectal cancer. As with the initial report by Heald et al., there were metastatic foci of cancer within the mesorectum in distance from the distal margin of the tumor itself; it follows that the removal of the mesorectum along with the resection of the rectum, would remove all microscopic unseen residual disease, hence increasing survival by increasing true R0 resections.

It is undisputable that any R1 resection will have a worse survival outcome in comparison to an R0 oncologic procedure. The same applies to pancreatic cancer with patients undergoing an R1 pancreatic resection having significant less survival and increased rate of locoregional recurrence [28]. Furthermore, in the majority of cases with R1 margins, the residual disease is located at the retroperitoneal dissection surface, the so-called “mesopancreas” [28, 29]. However the discrimination criteria between R0 and R1 resections has been a topic of active debate. Although in the United States R1 is the presence of microscopic residual tumor at the resection margin, in contrast in Europe according to the Royal College of Pathologists Guidelines, residual tumor within 1mm from the resection margin should be considered as R1 resection [29]. The necessity of at least 1mm free resection margin appears to be supported from the results from recent studies from USA, where the survival benefit of an R0 resection is abolished when the tumor is located within 1mm from the resection margin [30]. The debate on the definition of resection margins is a factor of utmost importance and should always be taken into account, as it may have a significant bias effect on the results reported by different centres [31]; to this end the need of a universal standardized method of pathology reporting is crucial in order to have truly comparable multicentric randomized control trials on pancreatic cancer.

The retropancreatic soft tissue also referred as “mesopancreas” consists of loose areolar and adipose tissue, lymphatics, capillaries and nerve fibers [11]. Pancreatic adenocarcinoma is known to microsopically infiltrate the retroperitoneal space involving the lymphatics and nerve plexuses [32]. Hence, it only seems reasonable to expand the dissection during pancreatoduodenectomy to the retroperitoneal space in order to resect the area of the “mesopancreas”, since within this area there are abundant lymphatics and capillaries, which could have been infiltrated by cancer cells. However infiltration of the “mesopancreas” prompts a skeptical query: when the “mesopancreas” is infiltrated are we looking towards a T4+ and/or an N+ and/or an M1 tumor? In order to assess the oncological value of “mesopancreas” resection, there is a need of survival studies in pancreatic cancer, where a stratification of patients should be made based on the infiltration of mesopancreas and the survival to be compared with the survival of patients with either T4 tumors, or N1 disease or M1 disease.

To our knowledge, there are no randomized control trials comparing the oncologic effect of “mesopancreas” excision. The decision of “mesopancreas” excision is usually made based on tumor size and the intraoperative estimation of possible infiltration of this space. However it would be irrational not to excise the retropancreatic area in the setting of a large tumor, who possibly has infiltrated this space. A possible way forward on the need of “mesopancreas” resection in gaining a survival benefit, would be survival studies among patients with small tumors (T1 or T2), who will be randomly allocated to either standard pancreatectomy or standard pancreatectomy with “mesopancreas” excision.

In the published consensus on the definition of standard and extended pancretoduodenectomy by the international Study Group on Pancreatic Surgery, although a detailed description of the extent of resected organs is described, no mention was made to the retropancreatic area [33]. As expected, this consensus has raised concerns whether “a leave alone” policy will increase the number of R1 resections [34], concerns that we share ourselves. The dissection of the retropancreatic retroperitoneum is an area abundant with organ-essentials structures such as the celiac trunk artery, the superior mesenteric vessels and their corresponding nerve plexuses. Surely the approach to this anatomical area is at least challenging and surgical expertise is warranted, however to our view it maybe oncologically necessary.

Apart from the oncological necessity of achieving an R0 resection in pancreatic surgery, a factor that should not be overlooked is the postoperative morbidity and mortality. Pancreatoduodenectomy is still associated with substantial morbidity, although the experience of the operating surgeon and the hospital within a pancreatoduodenectomy is performed, significantly affects the postoperative short-term outcomes [35]. As expected, every kind of extended resection in pancreatic surgery (either extended pancreatoduodenectomy or extended lymphadenectomy) is associated with increased postoperative morbidity [20-22, 33]. However as with all malignancies the oncological management of the patient incorporates adjuvant therapies, especially in patients with advanced tumors. Hence it is of utmost importance the patient to receive his adjuvant therapy as soon as possible. An increased postoperative morbidity and surgery-related complications, increase the interval between surgery and adjuvant therapy, which in turn has been shown to annul the oncologic efficacy of an R0 pancreatectomy [36]. Therefore a cautious “risk-tobenefit” consideration should always take place balancing the risks of an extended procedure versus the benefit of an R0 resection.


Pancreatic cancer remains a malignancy with grim prognosis. It is undisputable that surgical resection by means of pancreatoduodenectomy is the only treatment with curative intent and every effort should be made for this procedure to achieve the best locoregional control of the disease, i.e. R0 resection. Extended lymphadenectomy during pancreatectomy has failed to prove any survival benefit. However up to today there is no available evidence to terminate pancreatic resection when evident resectable node disease is encountered intraoperatively, outside the proposed field of dissection. No attempts to resect this lymph node disease will deem the resection itself inadequate (R2 resection).

“Mesopancreas” refers to the retropancreatic retroperitoneal soft tissue, although anatomically the term may not be appropriate. The oncological value of “mesopancreas” excision has not yet been evaluated within the setting of a randomized control trial and similarly to the extended lymphadenectomies, when there is evident or possible invasion of this area, every effort should be made to achieve R0 resection. Furthermore, the oncological value of the combined effect of “mesopancreas” excision and extended lymphadenectomy has not yet been assessed within the setting of a randomized control trial.

Overall, R0 resection is the main goal of pancreatoduodenectomy for pancreatic head cancer. An equally important goal is to minimize the pancreatectomy associated morbidity as the timely commencement of adjuvant chemotherapy improves the oncological outcome in these patients.

Conflict of interest

All the authors have no conflicts of interest


  1. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, Ellis L, Walters S, Forman D, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancer Oncol 2009;10:351-69. [PMID: 19303813]
  2. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 2015;385:1206-18. [PMID: 25479696]
  3. Gaedcke J, Gunawan B, Grade M, Szoke R, Liersch T, Becker H, Ghadimi BM. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langebecks Arch Surg 2010;395:451-458. [PMID: 19418067]
  4. Hoem D, Viste A. Improving survival following surgery for pancreatic ductal adenocarcinoma- A ten-year experience. Eur J Surg Oncol 2013;38:245-251. [PMID: 22217907]
  5. Evans DB, Lee JE, Tamm EP, Pisters P. Pancreatoduodenectomy(whipple operation) and total pancreatectomy for cancer. In mastery of surgery, Williams & Wilkins 2007, Philadelphia, PA 19106 USA, 113:1299-1317.
  6. Gockel I, Domeyer M, Wolloscheck T, Konerding MA, Junginger T. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World J Surg Oncol 2007; 5:44. [PMID: 17459163]
  7. Kay AW. Reflections of Sir Andrew Watt Kay. ContempSurg 1978;13:71.
  8. Scandalakis JE, Skandalakis LJ, Kingsnorth AN, Colborn GL, Weidman TA, Scandalakis PN. Pancreas. In skandalakis' surgical anatomy- the embryologic and anatomic basis of modern surgery. Paschalidis Medical Publications 2004, Athens 11527, Greece, 21:1151-1228.
  9. Kitagawa H, Ohta T, Makino I, Tani T, Tajima H, Nakagawara H, Ohnishi I, Takamura H, et al. Carcinomas of the ventral and dorsal pancreas exhibit different patterns of lymphatic spread. Front Biosci 2008;13:2728-35. [PMID: 17981748]
  10. Adham M, Singhirunnusorn J. Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors. Eur J Surg Oncol 2012;38:340-345. [PMID: 22264964]
  11. Agrawal MK, Thakur DS, Somashekar U, Chandrakar SK, Sharma D. Mesopancreas: myth or reality. JOP 2010;11:230-3. [PMID: 20442517]
  12. Mirilas P, Siatitsas Y, Scandalakis JE. Benign anatomical mistakes: inferior pulmonary ligament. Am Surg 2002;68:922-6. [PMID: 12412727]
  13. Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery 1973;73:307-320. [PMID: 4265314]
  14. Penberthy DR, Rich TA, Adams RB. Postoperative adjuvant therapy for pancreatic cancer. Semin Surg Oncol 2003;21:256-60. [PMID: 14648783]
  15. Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Iwanaga T. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988;208: 215-220. [PMID: 2840866]
  16. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Klöppel G, Dhaene K, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter prospective randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-517. [PMID: 9790340]
  17. Farnell MB, Peason RK, Sarr GM, DiMagno EP, Burgart LJ, Dahi TR, Foster N, Sargent DJ, et al. A prospective randomized trial comparing standard pancreatodudenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-30. [PMID: 16269290]
  18. Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, Abrams RA, Laheru D, et al. Pancreaticoduodenectomy With or Without Distal Gastrectomy and Extended Retroperitoneal Lymphadenectomy for PeriampullaryAdencarcinoma - Part 3: Update on 5-Year Survival. J Gastrointest Surg 2005;9:1191-1206. [PMID: 16332474]
  19. Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, Miyagawa S, Yamaguchi A, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012;19:230-41. [PMID: 22038501]
  20. Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreatoduodenectomy for pancreatic cancer. Br J Surg 2007;94:265-73. [PMID: 17318801]
  21. Xu X, Zhang H, Zhou P, Chen L. Meta-analysis of the efficacy of pancreatoduodenectomy with extended lymphadenectomy in the treatment of pancreatic cancer. World J Surg Oncol 2013;11:311. [PMID: 24321394]
  22. Ke K, Chen W, Chen Y. Standard and extended lymphadenectomy for adenocarcinoma of the pancreatic head: a meta-analysis and systematic review. J Gastroenterol Hepatol 2014;29:453-62. [PMID: 24164704]
  23. Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin TT , Hayashi M, Yamada S, et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas 2011;40:951-5. [PMID: 21441841]
  24. Pai RK, Beck AH, Mitchem J, Linehan DC, Chang DT, Norton JA, Pai RK. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Am J Surg Pathol 2011;35:228-34. [PMID: 21263243]
  25. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Yuasa Y, Sueda T. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg 2010;34:1900-7. [PMID: 20376442]
  26. Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andrén-Sandberg A, Asbun HJ, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the internationall Study Group on Pancreatic Surgery (ISGPS). Surgery 2014;156:591-600. [PMID: 25061003]
  27. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 1982;69:613-6. [PMID: 6751457]
  28. Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery 2012;152:S103-11. [PMID: 22766366]
  29. Peparini N, Chirletti P. Mesopancreas: A boundless structure, namely R1 risk in pancreatoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2013:1303-08. [PMID: 24188796]
  30. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, et al. Panceratic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg 2013;257:731-6. [PMID: 22968073]
  31. Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 2012;99: 1036-49. [PMID: 22517199]
  32. Ishikawa O, Wada H, Ohigashi H, Doki Y, Yokoyama S, Noura S, Yamada T, Sasaki Y, et al. Postoperative cytology for drained fluid from the pancreatic bed after “curative resction of pancreatic cancers: does it predict both the patient's prognosis and the site of cancer recurrence? Ann Surg 2003;238:103-10. [PMID: 12832972]
  33. Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, Andrén-Sandberg A, Asbun HJ, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery. Surgery 2014;156:1-14. [PMID: 24856668]
  34. Peparini N. Resection of the mesopancreas in pancreatic head adenocarcinoma: Is it outside of the International Study Group on Pancreatic Surgery definition and consensus statement for standard and extended pancreatectomy? Surgery 2015; 158:310-1. [PMID: 25704416]
  35. Gooiker GA, van Gijn W, Wouters MW, Post PN, van de Velde CJ, Tollenaar RA et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011;98:485-94. [PMID: 21500187]
  36. Kang CM, Kim DH, Choi GH, Kim KS, Choi JS, Lee WJ. Detrimental effect of postoperative complications on oncologc efficacy of R0 pancreatectomy in ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2009;13:907-14. [PMID: 19224295]